HER2-Positive Breast Cancer | Topics

 
Radiation Therapy Omission Not Advised in Early-Stage HER2+ Breast Cancer
April 04, 2021

In a retrospective review published in NPJ Breast Cancer, data indicate that omitting radiation therapy results in decreased overall survival in patients with stage I HER2-positive breast cancer.

Pyrotinib and Capecitabine Combo Improved PFS Compared to Lapatinib Plus Capecitabine for HER2-Positive Breast Cancer
March 24, 2021

Pyrotinib plus capecitabine to treat patients with HER2-positive metastatic breast cancer saw a statistically significant improvement in progression-free survival.

Potential Novel Therapies Emerge for Third-Line Setting in Patients with HER2+ Metastatic Breast Cancer
March 06, 2021

Sara A. Hurvitz, MD, FACP, of the University of California, Los Angeles, discussed a number of emerging novel therapies with the potential to treat patients with HER2-positive metastatic breast cancer in the third-line setting.